Detection of spike-modRNA

Detection of vaccine modRNA in immune cells and tissue samples by in-situ hybridisation

This detection is purely qualitative. Similar to immunohistochemistry, individual positive cells in the sample materials are stained and visualised microscopically. In contrast to immunohistochemistry, in which the spike protein is detected via antibodies, in-situ hybridisation detects the modRNA contained in the ‘vaccine’ via a specific RNA probe. To ensure specificity for the vaccine mRNA, the detection of viral RNA is also analysed at the same time, which should be positive in the case of an infection, but negative after vaccination alone (without previous or subsequent infection).

The in-situ hybridisation is significantly more time-consuming and therefore also more expensive than immunohistochemistry. It is therefore mainly recommended for further diagnostics in the event of a positive immunohistochemistry result. However, it cannot be completely ruled out that mRNA may be present and may also cause inflammatory symptoms without spike protein being detected in the tissue. If there is reasonable suspicion, in-situ hybridisation should therefore be considered even if immunohistochemistry is negative.

Detection of spike protein or ‘vaccine mRNA’ in immune cells and tissue samples

The two methods described above can also be applied to tissue or immune cells initially isolated from whole blood or cerebrospinal fluid. Positive detection indicates persistent vaccine activity and thus also the possibility of still active and progressive vaccine damage, especially damage to the immune system.